These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. A post hoc analysis of the long-term safety and efficacy of perampanel in Asian patients with epilepsy. Inoue Y, Kaneko S, Hsieh PF, Meshram C, Lee SA, Aziz ZA, Nabangchang C, Dash A. Epilepsia; 2019 Mar; 60 Suppl 1():60-67. PubMed ID: 30869167 [Abstract] [Full Text] [Related]
30. Perampanel for the treatment of people with idiopathic generalized epilepsy in clinical practice. Trinka E, Alsaadi T, Goji H, Maehara T, Takahashi S, Jacobs J, Renna R, Gil-López FJ, McMurray R, Sáinz-Fuertes R, Villanueva V. Epilepsia; 2023 Aug; 64(8):2094-2107. PubMed ID: 37114853 [Abstract] [Full Text] [Related]
33. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study. Singh K, Shah YD, Luciano D, Friedman D, Devinsky O, Kothare SV. Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147 [Abstract] [Full Text] [Related]
34. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Gidal BE, Laurenza A, Hussein Z, Yang H, Fain R, Edelstein J, Kumar D, Ferry J. Neurology; 2015 May 12; 84(19):1972-80. PubMed ID: 25878177 [Abstract] [Full Text] [Related]
36. Perampanel as monotherapy or first adjunctive therapy in pediatric and adult patients with epilepsy: the first United States-based phase IV open-label ELEVATE study. Punia V, Klein P, Mihaylova T, Biton V, Samad O, Ngo LY, Kumar D, Malhotra M. J Neurol; 2024 Jul 12; 271(7):4587-4598. PubMed ID: 38730096 [Abstract] [Full Text] [Related]
37. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings. Tsai JJ, Wu T, Leung H, Desudchit T, Tiamkao S, Lim KS, Dash A. Acta Neurol Scand; 2018 Apr 12; 137(4):378-391. PubMed ID: 29214650 [Abstract] [Full Text] [Related]
39. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study. Villanueva V, Garcés M, López-González FJ, Rodriguez-Osorio X, Toledo M, Salas-Puig J, González-Cuevas M, Campos D, Serratosa JM, González-Giráldez B, Mauri JA, Camacho JL, Suller A, Carreño M, Gómez JB, Montoya J, Rodríguez-Uranga J, Saiz-Diaz R, González-de la Aleja J, Castillo A, López-Trigo J, Poza JJ, Flores J, Querol R, Ojeda J, Giner P, Molins A, Esteve P, Baiges JJ. Epilepsy Res; 2016 Oct 12; 126():201-10. PubMed ID: 27521586 [Abstract] [Full Text] [Related]
40. Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes. Sagar P, Wawryk O, Vogrin S, Whitham E, Kiley M, Frasca J, Carne R, Seneviratne U, Cook MJ, Lawn N, Nikpour A, D'Souza WJ. Epilepsy Behav; 2021 Jun 12; 119():107935. PubMed ID: 33930626 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]